Search results
Sarepta (SRPT) Stock Up 76.8% in Three Months: Here's Why
Zacks via Yahoo Finance· 2 years agoSarepta Therapeutics (SRPT) is progressing with the development of its pipeline, which focuses on...
Why Sarepta's (SRPT) Stock Price Moved Up 17% on Tuesday
Zacks via Yahoo Finance· 5 months agoSarepta (SRPT) surges after its CEO made positive comments on the label expansion filing for the...
Sarepta data show new Duchenne drug’s potency, but highlight side effects
BioPharma Dive via Yahoo Finance· 4 months agoA successor medicine to Sarepta's Exondys 51 appeared better at boosting dystrophin protein...
Sarepta (SRPT) Sells Priority Review Voucher for $102M
Zacks via Yahoo Finance· 11 months agoSarepta (SRPT) sells its priority review voucher that was awarded following the FDA's approval to...
1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock?
Motley Fool via Yahoo Finance· 4 months agoIn biotech, it's often difficult to tell whether bad news for one company will also be bad news for...
US FDA approves Sarepta's gene therapy for rare muscular dystrophy in some kids
Reuters via Yahoo News· 12 months agoThe U.S. health regulator has granted accelerated approval to Sarepta Therapeutics'...
A Comprehensive Look at Sarepta's Growth and Innovation
GuruFocus.com via Yahoo Finance· 2 months agoSarepta Therapeutics, Inc. (NASDAQ:SRPT) is an American pharmaceutical company leading the global...
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
Motley Fool via Yahoo Finance· 6 months agoCould the rare-disease-focused biotech Sarepta Therapeutics (NASDAQ: SRPT) one day become a...
Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today
Motley Fool via Yahoo Finance· 5 months agoSarepta Therapeutics (NASDAQ: SRPT) saw a lot of love from the market as the trading week kicked off...
Sarepta Therapeutics (SRPT) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 3 months agoImage source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q4 2023 Earnings Call Feb 28,...